- Trevena continues to struggle to get OLINVYK off the launch pad. COVID-19 headwinds are persisting, and it is having an impact on the company's ability to get through P&T committees.
- Trevena is building a body of evidence in OLINVYK's post-approval program. The company expects these additional studies should improve product adoption and potentially expand OLINVYK's label.
- The market has crushed the share price under anemic volume. Now, TRVN's market cap is struggling to stay above $100M. I believe TRVN offers a great risk-reward at these prices.
- My "house money" position has gone from comfortably green, to a deep dark red. I am looking to change my strategy to claw my way back into green.
For further details see:
Trevena Offers An Enticing Risk-Reward At These Prices